Treatment of chemotherapy-induced anemia in ovarian cancer patients: Does the use of erythropoiesis-stimulating agents worsen survival?

International Journal of Gynecological Cancer

Volumn 22, Issue 5, 2012, Pages 786-791

  Rocconi, Rodney P ^a   Sullivan, Paula ^a   Long, Beverly ^a   Blaize, Marie ^b   Brown, Jennifer ^b   Arbuckle, Janeen ^b   Bevis, Kerri ^b   Estes, Jacob M ^b   Reed, Eddie ^a   Finan, Michael A ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chemotherapy induced anemia; Erythropoiesis stimulating agents; Ovarian cancer; Survival

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC METAL COMPLEX; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE; RECURRENT CANCER; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84863648480     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31825104f4     Document Type: Article

References (22)

1. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5:353-360.
2. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev. 2004;30:563-575. (Pubitemid 39157855)
3. Case AS, Rocconi RP, Kilgore LC, et al. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Gynecol Oncol. 2006;101:499-502. (Pubitemid 44251069)
4. Chang J, Couture FA, Young SD, et al. Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther. 2004;2:52-58.
5. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol. 1998;9:255-260. (Pubitemid 28186794)
6. Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31:2416-2432.
7. Crouch Z, DeSantis ER. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review. Am J Health Syst Pharm. 2009;66:1180-1185.
8. Lind M, Vernon C, Cruickshank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer. 2002;86:1243-1249.
9. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260. (Pubitemid 37324251)
10. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394-403. (Pubitemid 36951623)
11. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
12. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonYsmall-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032. (Pubitemid 46596751)
13. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714. (Pubitemid 43821788)
14. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407.
15. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214. (Pubitemid 32816195)
16. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
17. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62-E71.
18. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
19. Release EP. Available at: www.emea.europa.eu/pdfs/human/press/pr/ 33396308en.pdf. Accessed October 2010.
20. Release FP. Available at: www.fda.gov/medwatch/safety/2008/ESA-DHCP- Aug2008.pdf. Accessed October 2010.
21. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.
22. National Comprehensive Cancer Network (NCCN) Guidelines. Available at: www.nccn.org. Accessed October 2010.